Abstract
The recent biochemical demonstration of the association of the μ-opioid receptor (MOR) with Gαs that increases after long-term morphine treatment (Mol Brain Res135:217–224, 2005) provides a new imperative for studying MOR-Gαs interactions and the mechanisms that modulate it. A persisting challenge is to elucidate those neurochemical parameters modulated by long-term morphine treatment that facilitate MOR-Gαs association. This study demonstrates that 1) Gαs exists as a phosphoprotein, 2) the stoichiometry of Gαs phosphorylation decreases after long-term morphine treatment, and 3) in vitro dephosphorylation of Gαs increases its association with MOR. Furthermore, our data suggest that increased association of Gαs with protein phosphatase 2A is functionally linked to the long-term morphine treatment-induced reduction in Gαs phosphorylation. These findings are observed in MOR-Chinese hamster ovary and F11 cells as well as spinal cord, indicating that they are not idiosyncratic to the particular cell line used or a “culture” phenomenon and generalize to complex neural tissue. Taken together, these results indicate that the phosphorylation state of Gαs is a critical determinant of its interaction with MOR. Long-term morphine treatment decreases Gαs phosphorylation, which is a key mechanism underlying the previously demonstrated increased association of MOR and Gαs in opioid tolerant tissue.
Footnotes
-
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
-
doi:10.1124/mol.107.036145.
-
ABBREVIATIONS: MOR, μ-opioid receptor; IP, immunoprecipitate; AC, adenylyl cyclase; CHO, Chinese hamster ovary; MOR-CHO, Chinese hamster ovary cells stably transfected with MOR; PP2A, protein phosphatase 2A; DMEM, Dulbecco's modified Eagle's medium; DTT, dithiothreitol; PP1, protein phosphatase 1; PP2A, protein phosphatase 2A; aa, amino acids; rGαs, recombinant purified Gαs; PKC, protein kinase C; GTPγS, guanosine 5′-O-(2-[35S]thio)triphosphate; Pi, inorganic phosphate.
- Received March 19, 2007.
- Accepted June 15, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|